Terms ending in 2037
Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,507,196 | Neurodevelopmental Disorder Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,888,543 | Neurodevelopmental Disorder Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,446,275 | Neurodevelopmental Disorder Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,839,600 | Neurodevelopmental Disorder Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,734,147 | Neurodevelopmental Disorder Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,426,754 | A Crystalline Form of ANAVEX2-73 for the Treatment of Alzheimer's Disease In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,103,478 | Anavex2-73 for the Treatment of Alzheimer's Disease In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,813,242 | A2-73 as a Therapeutic for Insomnia, Anxiety, and Agitation In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,285,403 | A2-73 as a Therapeutic for Insomnia, Anxiety and Agitation In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.